Volume 8, Abstract Book BHS, February 2017



P38 Coexistence of inversion (16) et Bcr-Abl rearrangement in acute myeloid leulemia: a clinical description

J. Devreux, G. Di Prinzio, S. Bailly, S. Lefebvre, G. Verstraete, K. van Renterghem, A. Charlot, P. Saussoy, J-P. Defour, N. Straetmans, X. Poiré, L. Michaux, M-C. Vekemans, V. Havelange

P39 Respiratory illness in hematologic disorders: try to think of Pulmonary Alveolar Proteinosis and GATA-2.

A. Camboni, C. Dachelet, E. Van den Neste, L. Sacre, L. Marot

P40 Successful initial treatment of a cytopenic AML patient with pulmonary leukemic infiltration at diagnosis

I. Moors, P. Vlummens, C. Lecluyse, J. Vermassen

P41 A 54-year-old woman with a myeloid neoplasm associated with eosinophilia and t(5;12) (q33;p13)/PDGRFB rearrangement: case report and mini-review of the literature

Q. Delefortrie, F. Lambert, G. Bulliard, M. Jurdan, S. Toffoli, D. Sartenaer, S. De Prophetis, D. Pranger, A. Kornreich, P. Mineur

P56 Evaluation of Four Hemoglobin Separation Analyzers for Hemoglobinopathy Diagnosis

S. Degandt, R. Coens, K.V. van Maele, N. Verplancke, B. Cauwelier, H. Devos, M. Langlois, J. Emmerechts

P57 Comparison of the a-Globin StripAssay® and MLPA® as a diagnostic tool for a-thalassaemia

H. Claerhout, J. Oosterbosch, C.L. Harteveld, E. Lierman, D. Kieffer

P58 Extremely elevated C - reactive protein: a bad omen for haematological patients?

L. Tryssesoone, D. Deeren

P59 Automatic clustering of cell populations characterized by immunophenotyping

C. Gosset, J. Foguenne, M. Simul, A. Keutgens, F. Tassin, A. Gothot

P60 A rare case of ‘Thrombocytosis’

F.M. Maerevoet, M. Elouaaliti, A. Cantinieaux, M. Spilleboudt, M. Vercruyssen, D. Bron, N. Meuleman

P61 A deadly sore throat: acquired-TTP or Clindamycin induced thrombotic microangiopathy

A. Papaleo, M. Libertalis, M. Vekemans

P62 Absence of fragmented red cells (FRC) measured on Sysmex XN® could be useful to exclude FRC presence on blood smears

V.T.P. Nguyen, H. Kandet, R. Li, B. Cantinieaux

P63 Follicular dendritic cell sarcoma: report of a case and review of the literature

V. Galle, S. Verbeke, W. Ceelen, I. Moors

P64 Hemolytic anemia in a progressive breast cancer: think about thrombotic microangiopathy and treat the cancer

S. Bailly, M-C. Vekemans, B. Chatelain, M. André, T. Vander Borght, L. D’Hondt, L. Faugeras, G. Verstraete, J. Devreux, G. Di Prinzio, S. Lefevre

P75 Implementation of Releasing Time to Care - the Productive Hematology Ward

E. Boon, H. Bolckmans, K. Bal, S. Slootmans, A.L. van de Velde, A. Devos

P76 PrimeFlow™ RNA Assay: a novel technique for single-cell expression analysis in heterogeneous cell populations

B. Depreter, M. Meul, B. Denys, B. De Moerloose, E. Terras, K. Vandepoele, J. Philippé, T. Lammens

P77 High dose therapy and autologous stem cell transplantation in gynaecological malignancies: a monocentric retrospective study

M. Nderlita, I. Vergote, D. Dierickx

P78 Outcome of patients with hepatic sinusoidal obstruction syndrome admitted in the intensive care unit

A. Jaspers

P79 Atypical bone pain after allogeneic bone marrow transplantation for myelofibrosis

G. Verstraete, S. Lefevre, S. Bailly, G. Di Prinzio, J. Devreux, J-P. Defour, P. D’Abadie, P. Van Eeckhout, F. Kino, C. Goemare, N. Lepage, L. Michaux, V. Havelange, E. Van den Neste, C. Lambert, L. Knoops, M-C. Vekemans, X. Poiré

PP01 Mucosal- associated invariant T cells deficiency in multiple myeloma can be overcome by PD-1 inhibition

M. Favreau, K. Venken, S. Faict, K. Maes, K. De Veirman, E. De Bruyne, X. Leleu, D. Elewaut, K. Vanderkerken, E. Menu

PP02 The histone methyltransferases G9a/GLP: new promising targets for the treatment of multiple myeloma

E. De Smedt, J. Devin, H. Liu, A. Maes, K. Maes, K. De Veirman, E. Menu, K. Vanderkerken, J. Moreaux, E. De Bruyne

PP03 The anaphase-promoting-complex/ cyclosome: a new promising target in mantle cell lymphoma and diffuse large B cell lymphoma

A. Maes, E. De Smedt, K. De Veirman, K. Maes, E. Menu, E. Van Valckenborgh, K. Vanderkerken, E. De Bruyne

PP04 Light chain IgLV3-21 is associated with poor prognosis in Chronic Lymphocytic Leukemia patients independently of the presence of heavy chain IgHV3-21

B. Stamatopoulos, T. Smith, D. Sims, A. Heger, H. Dreau, A. Schuh

PP05 The detection rate of PET/CT after co-administration of [18F]NaF and [18F]FDG is superior to the detection rate of whole-body MRI in the diagnosis of MM lesions

J. Caers, N. Withofs, F. Cousin, T. Tancredi, P. Simoni, B. De Prijck, K. Hafraoui, C. Bonnet, R. Heusschen, V. Alvarez-Miezentseva, R. Hustinx, Y. Beguin

PP30 Retrospective study of de novo and secondary myeloid sarcoma

S. van Aelst, H. Claerhout, C. Melis, T. Tousseyn, P. Vandenberghe, D. Dierickx, N. Boeckx

PP31 Roles of microRNAs in myeloid malignancies driven by activated tyrosine kinases

M. Claus, A. Essaghir, P. Saussoy, L. Michaux, J.B. Demoulin, V. Havelange

PP32 Retrospective real-world data confirms the efficacy and safety of decitabine in treating patients with acute myeloid leukemia in Belgium

B. Malfait, J. Braakman, L. de Vos, B. Bailly, I. Vande Broek, S. Meers, D. Dierickx

PP33 Targeted next-generation sequencing using a pan-myeloid panel in myelodysplastic neoplasms: implementation in clinical diagnostics

G. Froyen, J. Willemse, A. Broekmans, R. Smets, B. Cruys, N. Put, V. Madoe, M. Janssen, O. Soepenberg, G. Bries, B. Maes

PP34 The MLL partial tandem duplication (MLL-PTD) is correlated with WT1 overexpression in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and shows a similar expression profile during treatment

K. Vandepoele, B. Denys

PP50 Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice

G. Ehx, G. Fransolet, L. Delens, J. Muller, Y. Beguin, S. Humblet-Baron, M. Hannon, F. Baron

PP51 Impact of Th17 cell population on xenogeneic graft-versus-host disease

L. Delens

PP52 Daratumumab: Blessing for the patient, but hell for the clinical lab

C. van der Heijden, S. Mahieu

PP53 Unexplained anaemia in the Elderly: High prevalence of functional iron deficiency and underdiagnosed myelodysplasia

L. Sattar, M. Maerevoet, D. Bron, B. Cantinieaux, P. Hermans, T. Pepersack

PP54 Diagnosis of de novo thrombotic microangiopathy after kidney transplantation

B. Heymans, B. Sprangers, D. Dierickx

PP55 Post-transfusion HbS monitoring on TOSOH G8 in variant HbA1c mode

S. van Aelst, K. Desmet, E. Nackers, D. Kieffer

PP70 The use of adipose Stromal Vascular Fraction in a Platelet-Rich Fibrin scaffold within Bisphosphonate-Related Osteonecrosis of the Jaw treatment

C. Bouland, N. Meuleman, J. Widelec, K. Kambiz, C. Voisin, L. Lagneaux, P. Philippart

PP71 Impact of Tofacitinib on xenogeneic graft versus host disease

M. Hannon, C. Grégoire, J. Muller, G. Fransolet, L. Delens, Y. Beguin, G. Ehx, F. Baron

PP72 Transcription factors and checkpoint inhibitor expression with age: predictive markers of aging?

L. Dang, K. Willard-Gallo, S. Garaud, H. Duvillier, J.N. Lodewyckx, C. Solinas, P. de Silva, M. Berehab, C. Chunyan, C. Sibille, D. Bron

PP73 Loss of transfer RNA U34 modifying enzymes impairs hematopoietic stem and progenitor cell differentiation and function

A. Rosu, Q. Bai, E. Ramery, M. Thiry, P. Close, F. Bureau, C. Desmet

PP74 Limited impact of imatinib in a murine model of sclerodermatous chronic graft-versus-host disease

G. Fransolet, L. Belle, J. Somja, M. Binsfeld, P. Delvenne, P. Drion, M. Hannon, Y. Beguin, G. Ehx, F. Baron

P06 Targeted single cell sequencing unravels the heterogeneity of human T-cell acute lymphoblastic leukemia samples

J. de Bie, S. Demeyer, E. Geerdens, A. Uyttebroeck, N. Boeckx, J. Cools

P07 Unravelling oncogenic signalling induced by JAK3 mutations in a model of T-cell acute lymphoblastic leukemia (T-ALL)

I. Govaerts, S. Degryse, C. De Bock, K. Jacobs, S. Binos, M. Dun, J. Cools

P08 Immunotherapy in Multiple Myeloma using alfa-galactosylceramide loaded sEVs from dendritic cells to stimulate NKT activity

S. Faict, M. Favreau, E.D.B. E., K. De Veirman, K. Maes, K. Vanderkerken, R. Schots, E. Menu

P09 DARPin® molecule MP0250, a new antiangiogenic drug in multiple myeloma: An in vitro and in vivo study

K. De Veirman, L. Rao, M.A. Frassanito, V. Desantis, D. Giannico, L. di Marzo, U. Fiedler, A. Harstrick, D. Ribatti, K. Vanderkerken, A. Vacca

P10 The genetic landscape of the murine 5T models for multiple myeloma

K. Maes, B. Boeckx, L. De Beck, E. Menu, K. De Veirman, K. Vanderkerken, D. Lambrechts, E. De Bruyne

P11 Low-pass sequencing of plasma cell DNA and of circulating cell-free DNA for the detection of copy number aberrations and early response monitoring in multiple myeloma

B. Dewaele, S. Smits, L. Dehaspe, N. Brison, J. Ding, J. Van Houdt, H. Lemmens, L. Michaux, J. Vermeesch, P. Vandenberghe

P12 The glycan-binding galectin-1 is involved in osteoclast biology

J. Muller, M. Binsfeld, S. Dubois, G. Carmeliet, Y. Beguin, R. Heusschen, J. Caers

P13 Monoclonal Gammopathy of Undetermined Significance (MGUS) after kidney transplantation: prevalence and clinical significance

B. Heymans, D. Dierickx, B. Sprangers

P14 The impact of the updated IMWG diagnostic criteria in a real-life SMM cohort: a single center experience

P. Vlummens, F. Offner

P15 Treatment patterns of Waldenström’s macroglobulinemia in Belgium

A. Smet, V. Van Hende, M. André, C. Bonnet, G. Bries, V. De Wilde, H. Demuynck, N. Meuleman, W. Schroyens, A. Van Hoof, M. Giordan, L. de Vos, A. Janssens

P16 Real-Life Experience with Brentuximab Vedotin (Adcetris®): the Belgian National Registry

G. Verhoef, M. André, J. Imschoot, P. Graas, D. Bron

P17 Diagnostic strength of bone marrow aspirate versus biopsy in (smoldering) multiple myeloma patients

P. Vlummens, F. Offner

P18 Early discontinuation of lenalidomide in patients with relapsing or refractory multiple myeloma: predictive factors for stopping in the real life

A. Pistone, M. Maerevoet, S. Wittnebel, M. Vercruyssen, S. Buntinx, C. Spilleboudt, D. Bron, N. Meuleman

P19 Vanishing bile duct syndrome associated with diffuse large B-cell lymphoma

G. Dachy, T. Connerotte

P20 Results of laparoscopic splenectomy for benign and malignant hemopathies

D. Bron, A. Salaroli, N. Meuleman, M. Maerevoet, M. Vercruyssen, C. Spilleboudt, A. De Wind, G. Dapri, G.B. Cadiere, B. Cadiere

P21 Bone marrow necrosis with E. coli marrow invasion in a patient with secondary diffuse large B-cell lymphoma : a rare cause of pancytopenia

A. Delie, M. Hofmans, P. Vlummens

P22 Case report: Richter syndrome with plasmablastic lymphoma

A. Ladang, M. Simul, J. Somja, J. Foguenne, A. Gothot, A. Keutgens, F. Tassin

P23 Monoclonal gammopathy of clinical significance: about a case of pulmonary nodular amyloidosis

G. Di Prinzio, J. Devreux, S. Lefebvre, S. Bailly, G. Verstraete, A. Bourgois, C. Pedreira, J-P. Defour, A. Camboni, A. Marchandise, T. Pieters, M-C. Vekemans

P24 Flowcytometric detection of aberrant intraepithelial lymphocytes in refractory celiac disease

N. Boeckx, G. Verhoef, M. Hiele

P35 In-house developed 15-gene sequencing panel for acute myeloid leukemia and myelodysplasia allows robust detection of genetic defects including FLT3-ITD and CEBPA mutations

B. Denys, J. Van der Meulen, E. de Latter, S. Lefever, T. Rosseel, W. Steyaert, G. Vandercruyssen, I. Rottiers, D. Creytens, J. Van Dorpe, F. Speleman, B. Poppe, N. Van Roy, K. de Leeneer, K. Claes, K. Vandepoele

P36 Next generation sequencing in patients with therapy-related myeloid neoplasms

H. Claerhout, E. Lierman, D. Kieffer, N. Boeckx

P37 CD123 expression on acute leukemia blasts, hematogones, and monocytes; used as Minimal Residual Disease Marker

L. Rozen, L. Mekkaoui, C. Rassart, A. Janssens, D. Bron, A. Ferster, B. Cantinieaux